Search Results - theodore+deweese

4 Results Sort By:
BMETS Shared Decision Support Platform
Unmet NeedBone is the third most frequent site of tumor metastasis; it is estimated that 280,000 patients in the United States are living with symptomatic bone metastasis (SBM). Currently, physicians use their intuition and subjective experience with patients suffering from bone metastasis to make survival predictions that guide treatment decisions....
Published: 9/27/2024   |   Inventor(s): Sara Alcorn, Jacob Fiksel, Scott Zeger, Theodore DeWeese, Thomas Smith, Todd Mcnutt, Jean Wright, Chen Hu, Lawrence Kleinberg, Christen Elledge
Keywords(s):  
Category(s): Technology Classifications > Computers, Electronics & Software > Artificial Intelligence, Technology Classifications > Computers, Electronics & Software > Machine Learning, Technology Classifications > Diagnostics > Prognostic Biomarkers
Oncospace: An Analytical Database and Website for Personalized Medicine and Data Sharing in Radiation Oncology
The Oncospace database aggregates treatment planning and clinical information about prior patients facilitating analysis and extraction of knowledge from prior courses of care. The goal is to use the knowledge to influence clinical decisions, quality and safety of care for new patients. This is accomplished through easy to use web based interfaces designed...
Published: 9/26/2024   |   Inventor(s): John Wong, Theodore DeWeese, Harry Quon, Kimberly Evans, Joseph Herman, Joseph Moore, Todd Mcnutt
Keywords(s): Clinical Workflow Management System, Clinical Workflow Management Tools, Communications System, Healthcare Management, Operations Management
Category(s): Technology Classifications > Computers, Electronics & Software > Clinical Management, Technology Classifications > Computers, Electronics & Software > Healthcare IT, Technology Classifications > Computers, Electronics & Software
Irreversible Inhibitors of DNA Polymerase (Beta)
Unmet Need: Targeted cancer therapies against DNA repair enzymes have successfully been implemented in cancer treatments but now suffer from the development of drug resistance. There is a need for additional DNA repair enzyme targets to overcome current resistance issues. Technical Details: Johns Hopkins researchers have identified an inhibitor of DNA...
Published: 9/26/2024   |   Inventor(s): Mohammad Hedayati, Dumitru Arian, Theodore DeWeese, Marc Greenberg
Keywords(s): Antagonists/Inhibitors, Cancers, Disease Indication, Novel, Predicted Novelty, Prostate Cancer, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Men's Health, Clinical and Disease Specializations > Oncology > Prostate Cancer, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities
Radiation Sensitization Agents for Prostate Cancer
Radiation Sensitization Agents for Prostate CancerJHU REF: [C11146]  Invention novelty: A new mechanism to selectively sensitize the prostate to radiation therapy by knocking down DNA repair gene transcripts. Value Proposition: Current dose-escalated radiation therapy for localized prostate cancer treatment has increased the risk of injury of surrounding...
Published: 9/26/2024   |   Inventor(s): Xiaohua Ni, Yonggang Zhang, Theodore DeWeese, Shawn Lupold
Keywords(s): Biologics, Cancers, Disease Indication, Nucleic Acid, Prostate Cancer, Radiotherapy, Single, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Men's Health, Clinical and Disease Specializations > Oncology > Prostate Cancer, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Gene Therapies, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum